false
0001553788
0001553788
2026-07-28
2026-07-28
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
July 28, 2026
SPLASH BEVERAGE GROUP, INC.
(Exact name of registrant as specified in its charter)
| Nevada |
|
001-40471 |
|
34-1720075 |
|
(State or other Jurisdiction
of Incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification No.) |
|
1112 N. Flagler Drive
Fort Lauderdale, Florida |
|
33304 |
| (Address of principal executive offices) |
|
(Zip Code) |
Registrant’s
telephone number, including area code: (954) 648-7238
(Former
name or former address, if changed since last report.): n/a
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
| ☐ |
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405)
or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities
registered pursuant to Section 12(b) of the Act:
| Title of Each Class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
| Common Stock, $0.001 par value |
|
SBEV |
|
NYSE American LLC |
Item 1.01 Entry into a Material Definitive Agreement
On July 28, 2026, Splash Beverage Group, Inc. (the
“Company”) and Argent BioPharma Limited (ASX/LSE: RGT) (the “Licensor”) entered into an addendum (the “Addendum”)
to that certain exclusive global license agreement for CannEpil®, dated July 6, 2026 (the “License Agreement”). Pursuant
to the Addendum, the License Agreement was amended to: (i) expand the field of use under the License Agreement to include veterinary applications;
(ii) provide for an amended royalty rate payable to the Licensor equal to 10% of Net Revenue (as defined in the License Agreement) attributable
to veterinary applications and 15% of Net Revenue attributable to human applications; and (iii) extend various deadlines provided for
under the License Agreement. The Company previously disclosed the License Agreement and filed a copy thereof as Exhibit 10.1 in the Company’s
Current Report on Form 8-K filed on July 6, 2026.
The foregoing description of the Addendum does not
purport to be complete and is qualified in its entirety by reference to the full text of the Addendum, a copy of which is filed as Exhibit
10.1 and is incorporated herein by reference.
Item 7.01 Regulation FD Disclosure
On July 29, 2026, Splash Beverage Group, Inc. issued
a press release announcing that it has expanded its exclusive global license for CannEpil® with Argent BioPharma Limited (ASX/LSE:
RGT) to include veterinary applications. A copy of the press release is furnished as Exhibit 99.1 of this Current Report on Form 8-K.
The information in this Item 7.01 (including Exhibit
99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”)
or otherwise subject to the liabilities under such section, and shall not be deemed to be incorporated by reference into any filing of
the Company under the Securities Act of 1933 or the Exchange Act.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
| Exhibit |
|
Description |
| 10.1 |
|
Addendum No. 1 to the Exclusive License Agreement, dated July 29, 2026, by and between the Company and Argent BioPharma Limited |
| 99.1 |
|
Press Release dated July 29,
2026 |
| 104 |
|
Cover Page Interactive Data File (embedded within the Inline
XBRL document) |
SIGNATURES
Pursuant to the requirements of
the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| |
SPLASH BEVERAGE GROUP, INC. |
| |
|
|
| Date: July 29, 2026 |
By: |
/s/ Brady Cobb |
| |
Name: |
Brady Cobb |
| |
Title: |
Interim Chief Executive Officer |
EXHIBIT 99.1
Splash Beverage Group Expands CannEpil® Platform
into Veterinary Therapeutics, Establishing Second FDA-Regulated Pharmaceutical Development Program
Expansion broadens CannEpil into veterinary therapeutics
as Splash advances its cannabinoid pharmaceutical development platform
FORT LAUDERDALE, Fla., July 29, 2026—
Splash Beverage Group, Inc. (NYSE American: SBEV) (“Splash” or the “Company”) today announced that it has expanded
its exclusive global license for CannEpil® to include veterinary therapeutic applications, creating a second regulated pharmaceutical
development platform alongside the Company’s existing human pharmaceutical program.
The expanded field of use grants Splash exclusive
worldwide rights to develop, manufacture, commercialize, market and distribute CannEpil for veterinary diseases and conditions.
CannEpil is a proprietary pharmaceutical-grade cannabinoid
formulation consisting of cannabidiol (CBD) and tetrahydrocannabinol (THC) isolates formulated in an oral liquid solution and manufactured
under European Union Good Manufacturing Practice (EU-GMP) standards. Originally developed as a potential treatment for drug-resistant
epilepsy, CannEpil has previously been supplied through physician-directed access programs in international markets and has been assigned
an Investigational New Drug (IND) application number by the U.S. Food and Drug Administration for its human development program.
Splash intends to initially evaluate CannEpil for
veterinary applications in companion-animal oncology and chronic pain management, with canine indications expected to represent the initial
development focus. The Company intends to pursue U.S. regulatory approval through the FDA Center for Veterinary Medicine’s Investigational
New Animal Drug (INAD) and Conditional Approval pathways.
Addressing Significant and Growing Companion-Animal
Markets
The Company’s veterinary expansion positions
CannEpil within two significant and growing areas of companion-animal medicine.
According to Grand View Research, the global veterinary
pain management market was valued at approximately $2.6 billion in 2024 and is projected to reach approximately $3.8 billion
by 2030, driven by increasing pet ownership, longer lifespans and growing demand for advanced veterinary care.
Companion-animal oncology represents another meaningful
opportunity. Independent industry estimates place the global veterinary oncology market between approximately $900 million and $1.7
billion, depending on the products and services included, with continued long-term growth expected.
The underlying patient population is substantial.
According to the Veterinary Cancer Society, one in four dogs will develop cancer during their lifetime, while approximately half
of dogs over the age of ten will develop cancer. The U.S. National Cancer Institute estimates that approximately six million dogs are
diagnosed with cancer each year in the United States.
“Expanding our exclusive CannEpil license
into veterinary medicine materially broadens the value of the platform and provides access to significant companion-animal oncology and
pain-management markets,” said Brady Cobb, Interim Chief Executive Officer of Splash Beverage Group. “Cancer and chronic
pain affect millions of companion animals, yet treatment options remain limited in many indications. We believe CannEpil’s pharmaceutical-grade
formulation warrants disciplined evaluation through the FDA veterinary process.”
Under the amendment, Splash will pay Argent BioPharma
Limited a 10% royalty on net revenues generated from veterinary applications of CannEpil.
The Company is also finalizing a strategic joint
venture with an established cannabinoid pharmaceutical company to lead CannEpil’s veterinary development program. The partner’s
executive leadership includes experienced pharmaceutical development professionals with a demonstrated track record of advancing cannabinoid-based
medicines through regulatory approval and commercialization. Splash expects to announce additional details regarding the collaboration
in the near future.
Executing a Diversified Cannabinoid Health Sciences
Strategy
“Our objective extends well beyond expanding
the licensed field of use,” Cobb continued. “We are assembling a world-class development platform around CannEpil by
partnering with experienced cannabinoid pharmaceutical executives who have successfully navigated complex regulatory pathways and helped
bring cannabinoid medicines to market. We believe pairing differentiated intellectual property with proven scientific and regulatory expertise
materially enhances our ability to create long-term shareholder value.”
“Splash is executing a disciplined strategy
to build a diversified cannabinoid health sciences platform by commercializing existing international pharmaceutical assets, advancing
FDA-regulated veterinary and human therapeutics, and developing innovative cannabinoid consumer wellness and beverage brands for global
markets. The expansion of CannEpil into veterinary medicine represents another important milestone in executing that strategy and further
positions Splash at the intersection of pharmaceutical innovation and cannabinoid science.”
The Company believes the expanded veterinary rights
complement its broader strategy of commercializing pharmaceutical cannabinoid assets across multiple regulated healthcare markets. Actual
development timelines, target indications, clinical requirements and regulatory pathways will be determined following engagement with
the FDA and other applicable regulatory authorities.
There can be no assurance that CannEpil will receive
Conditional Approval, full approval or any other regulatory authorization for veterinary use, or that any commercialization efforts will
be successful.
About CannEpil®
CannEpil® is a proprietary pharmaceutical-grade
cannabinoid formulation consisting of cannabidiol (CBD) and tetrahydrocannabinol (THC) isolates formulated in an oral liquid solution
and manufactured under European Union Good Manufacturing Practice (EU-GMP) standards. Originally developed for drug-resistant epilepsy,
CannEpil has previously been supplied through physician-directed access pathways in select international markets and is being advanced
for additional pharmaceutical indications.
About Splash Beverage Group, Inc.
Splash Beverage Group, Inc. (NYSE American: SBEV)
is a publicly traded company headquartered in Fort Lauderdale, Florida. The Company is pursuing a strategic transformation toward becoming
a cannabinoid health, wellness, and biopharmaceutical platform through disciplined capital allocation, strategic investments, acquisitions,
and other platform-building initiatives.
More Information
Splash Beverage Group
Contact Information
Splash Beverage Group
Info@SplashBeverageGroup.com
Media Contact
Angela Gorman
AMWPR
angela@amwpr.com
917-348-0083
Forward-Looking Statements
This press release contains forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements
regarding the Company’s plans to develop and commercialize CannEpil for veterinary applications; anticipated regulatory pathways,
including the FDA Center for Veterinary Medicine’s Investigational New Animal Drug (INAD) and Conditional Approval processes; estimates
and projections for the market for veterinary treatments including oncology and pain management uses, the completion of a proposed joint
venture; the anticipated capabilities and experience of prospective development partners; the commercialization of international pharmaceutical
assets; the development of additional cannabinoid therapeutics, wellness and beverage products; and the Company’s broader strategic
initiatives including its strtagy of commercializing pharmaceutical cannabinoid assets across multiple regulated healthcare markets. Forward-looking
statements are prefaced by words such as “anticipate,” “expect,” “plan,” “could,” “may,”
“will,” “should,” “would,” “intend,” “potential,” “believe,” “estimate,”
“forecast,” “project,” and similar words.
Forward-looking statements are based on current expectations
and assumptions and involve known and unknown risks and uncertainties that could cause actual results to differ materially. Actual results
may differ materially from those contemplated by such forward-looking statements due to a variety of risks and uncertainties which include,
among others, the possibility that the license and our efforts to develop and commercialize the licensed product do not yield the benefits
anticipated or sought, the risk that we and the licensor are not able to obtain, maintain or protect intellectual property rights in the
licensed product in jurisdictions in which we seek to develop and commercialize the product and that competitors market the same or similar
products, our ability to negotiate ad execute a joint venture with a strategic collaborator to assist in our planned efforts in the veterinary
treatment space, our need to comply with contractual obligations to maintain our rights and develop and commercialize the licensed product,
our ability to raise the capital necessary to develop and commercialize the product and otherwise meet our working capital needs, our
need to comply with extensive regulations including clinical testing before we can market the product in applicable jurisdictions including
the U.S., our ability to recommence revenue generating activities with our limited staffing, and the status of evolving regulatory conditions
within the cannabinoid and wellness industries, and our ability to regain and maintain compliance with American listing standards. There
can be no assurance that CannEpil will receive regulatory approval for any indication or that any development or commercialization initiative
will achieve its intended results.
Additional information concerning these and other
risk factors is contained in the Company’s filings with the U.S. Securities and Exchange Commission, including its Annual Report
on Form 10-K for the year ended December 31, 2025 and the Final Prospectus on Form 424B3 filed on June 26, 2026. Any forward-looking statement
made by the Company speaks only as of the date on which it is made.
Readers are cautioned not to place undue reliance
on these forward-looking statements, which speak only as of the date made. Splash undertakes no obligation to update any forward-looking
statements, whether as a result of new information, future developments, or otherwise, except as required by applicable law.
